

# Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

## ARTICLE

# 7 Analysis of Nucleosides and Nucleobases by 8 Microemulsion Electrokinetic Capillary 9 Chromatography Coupled with Field-amplified 10 Sample Injection

1 Cite this: DOI: 10.1039/x0xx00000x

2 Received 00th January 2012,

3 Accepted 00th January 2012

4 DOI: 10.1039/x0xx00000x

5 www.rsc.org/

11 Yu He<sup>a</sup>, Wenmin Zhang<sup>a</sup>, Jinfeng Chen<sup>a</sup>, Fang Gu<sup>a</sup>, Jintian Cheng<sup>a</sup>, Lan  
12 Zhang<sup>a, b\*</sup>, Guonan Chen<sup>a\*</sup>

13 A microemulsion electrokinetic capillary chromatography (MEEKC) method was on-line coupled  
14 with field-amplified sample injection (FASI) for the analysis of nucleosides and nucleobases,  
15 namely cytidine, guanosine, N6-methyladenosine, fluorouracil, thymine, adenine, mercaptopurine,  
16 6-hydroxypurine, guanine. A microemulsion background electrolyte containing 10 mM sodium  
17 dodecyl sulfate (SDS), 0.6% (v/v) 1-butanol, 0.5% (v/v) ethyl acetate and 98.9% (v/v) borate  
18 buffer (10 mM; pH 9.0) was used as running buffer. An on-line field-amplified sample injection  
19 (FASI) technique was adopted to improve the detection sensitivity. Baseline separation of nine  
20 nucleosides was achieved within 12 min with the detection limits (S/N=3) between 0.22 and 2.97  
21 µg/mL with the DAD detector at 200 nm in the optimized conditions. The proposed method was  
22 applied to the determination of nine nucleoside compounds in spiked urine and serum samples  
23 with the recoveries ranged 91.2-113% and 85.2-112% and the relative standard deviation (RSDs,  
24 n=3) less than 5.90% and 8.22%, respectively.

25  
26  
27  
28  
29

## 30 Introduction

31 Nucleosides and nucleobases (i.e. nucleotides, bases and their  
32 analogues) are the primary substances constituting RNA and  
33 DNA and maintaining life activities of biological cell. Many  
34 diseases arise from the abnormality of nucleosides and their  
35 metabolites. Most of nucleosides with good physiological  
36 activities protect against herpes virus and retrovirus and have  
37 proven irreplaceability for physiology and pharmacology.<sup>1-3</sup>  
38 Nucleosides are playing increasing important role in antiviral,  
39 anti-tumour and anti-AIDS,<sup>4-6</sup> accounting  
40 for a substantial proportion of the antiviral drugs  
41 with the greatest potential after the sulfa drugs and antibiotics.<sup>7</sup>  
42 The drugs approved for anti-AIDS by the U.S. FDA, for  
43 example, are predominantly nucleoside derivatives.  
44 Additionally, the concentration changes of nucleosides in  
45 human urine can be a prognostic index of diseases.<sup>7</sup> Some  
46 modified nucleosides, as possible cancer biomarkers, have been  
47 shown to be abnormal amounts in urine of cancer patients and  
48 have been of interest since the 1970s.<sup>8-10</sup> Consequently, fast and  
49 efficient analysis of various nucleosides is an  
50 urgent and continuing topic in the field of  
51 natural pharmaceutical chemistry, pharmaceutical analysis and  
52 disease diagnosis.  
53 Nowadays, thin layer chromatography (TLC),<sup>11, 12</sup> gas  
54 chromatography (GC),<sup>13</sup> liquid chromatography-mass  
55 spectrometry (LC-MS),<sup>14, 15</sup> capillary electrophoresis (CE)<sup>10, 16</sup>,  
56 and capillary electrochromatography (CEC)<sup>18, 19</sup> have been  
57 employed as common method for separation and determination  
58 of nucleoside and their derivatives. The TLC has disadvantages  
59 of low sensitivity and limit of analytes. GC method usually  
60 requires complicated derivatization steps to improve the  
61 volatility of the test compounds. LC-MS method has been

1 demonstrated for the analysis of nucleosides compounds.  
 2 However, expensive equipments and large volumes of organic  
 3 solvents are always necessary. Even though CEC is fast,  
 4 efficient and less sample consumption, it is hindered by poor  
 5 reproducibility, easy bubble formation, relatively long  
 6 separation time and pH shifting.<sup>17</sup> In many cases, a more  
 7 efficient separation and determination technique is required  
 8 either to assess the levels of nucleosides or to further promote  
 9 the efficacy of the nucleoside drugs in biomedical science.




Fig.1 The chemical structures of 9 nucleoside compounds. 1, cytidine; 2, guanosine; 3, N6-methyladenosine; 4, fluorouracil; 5, Thymine; 6, Adenine; 7, mercaptopurine; 8, 6-hydroxypurine; 9, Guanine

## Experimental

### Chemicals

Cytidine, guanosine, N6-methyladenosine, fluorouracil, thymine, adenine, mercaptopurine, 6-hydroxypurine, guanine were obtained from J&K Chemical (Shanghai, China). Sodium dodecylsulfate (SDS) was purchased from Acros Organics (Geel, Belgium). Sodium tetraborate, 1-butanol, and ethyl acetate (analytical grade) were purchased from Kermel Chemical Reagents Development Centre (Tianjin, China). Acetonitrile (HPLC-grade) were provided by Sinopharm Chemical Reagents (Shanghai, China). An uncoated fused-silica capillary was product of Yongnian Optic Fiber Factory (Hebei, China). Water was purified using a Milli-Q system (Millipore, Bedford, MA, USA).

70

### Instrumentation

An Agilent CE3D system (Agilent Technologies, Waldbronn, Germany) equipped with a diode array detector (DAD) was employed for the separation and determination of the target analytes. Data acquisition and processing were performed with Agilent ChemStation software. All pH value of running buffer was measured by PHS-3C meter (Shanghai Dapu Instrument Company, Shanghai, China). Prior to use, all mobile phases for MEEKC were degassed with a KQ3200E ultrasonic bath (Kunshan, China).

81

### Preparation of running buffer for MEEKC

82

10 CE has been believed as a simple, rapid method for the  
 11 analysis of nucleoside and their derivatives. However, the close  
 12 isoelectric point (*pI*s) of nucleosides and analogues make them  
 13 difficult to be separated with conventional CE method.<sup>10, 16, 17</sup>  
 14 In the recent decades, a modified technique known as  
 15 microemulsion electrokinetic chromatography (MEEKC) with  
 16 an oil-in-water (o/w) microemulsion as alternative  
 17 pseudostationary phases (PSP) has been used to bioanalysis.<sup>20-</sup>  
 18 <sup>23</sup> MEEKC combines chromatographic partitioning between  
 19 two phases and electrokinetic migration. The separation  
 20 mechanism is very similar to Micellar electrokinetic capillary  
 21 chromatography (MEKC).<sup>20,24,25</sup> Furthermore, the  
 22 microemulsion structure increases fluidity, aiding in analyte  
 23 penetration and mass transfer. Meanwhile, the oil droplets in  
 24 microemulsions can be positively or negatively charged  
 25 depending on the surfactant to improve the separation.<sup>26</sup> By  
 26 changing the surfactant concentration and subsequently altering  
 27 the charge density of the aggregate, MEEKC is gifted with the  
 28 ability to extend the elution range of the separation.<sup>27</sup> The  
 29 features above which enables MEEKC the high efficiency  
 30 separation of charged or neutral analytes covering a wide range  
 31 of water solubility<sup>26</sup> and offers a large and flexible separation  
 32 capability for various analytes.

33 The low sensitivity of MEEKC coupling with UV detector, as  
 34 it happens with other CE modes, is due to the cell's short  
 35 optical path length, the small size of capillary and the limited  
 36 amount of sample injection.<sup>24, 26, 28</sup> Some sample concentration  
 37 steps are therefore necessary for improving the detection limit.  
 38 On-line enrichment technologies, such as field-amplified  
 39 sample injection (FASI), large volume sample stacking (LVSS)  
 40 and reversed electrode polarity stacking method was called for  
 41 settling this dilemma of MEEKC.<sup>22, 29-31</sup>

42 The aim of our study presented here was to develop a fast,  
 43 low-cost and sensitive FASI-MEEKC method for simultaneous  
 44 detection of nine nucleosides and nucleobases including normal  
 45 and modified nucleosides (structural formula shown in Fig.1).  
 46 The effects of microemulsion composition and separation  
 47 voltage were carefully chosen to optimize the separation.  
 48 Sample diluents and injection conditions, the essential factors  
 49 in FASI, were investigated in detail to improve the sensitivity.  
 50 This method was validated for the determination of nucleoside  
 51 compounds in urine and serum samples.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 Borate buffer was prepared from sodium tetraborate and the pH  
3 was adjusted with sodium hydroxide or hydrogen chloride.  
4 Microemulsions were prepared by mixing the appropriate ratio  
5 of components to obtain different microemulsion. Initially, the  
6 oil was mixed with the co-surfactant, and then the buffer  
7 containing surfactant was added. The optimum microemulsion  
8 consisted of 0.5 % ethyl acetate, 0.6 % (v/v) 1-butanol and  
9 10 mM borate buffer at pH 9.0 containing 10 mM SDS. The  
10 microemulsion was sonicated for 30 min to obtain the stable  
11 and optically transparent microemulsion system. The solutions  
12 were filtered through a 0.22  $\mu\text{m}$  microfilter prior to use.  
13

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

61 A series of borate buffers (10 mM) with the pH range from 8.0  
62 to 9.5 were accordingly investigated. The other compositions of  
63 microemulsion electrolyte were initially fixed in 10 mM  
64 sodium dodecyl sulfate (SDS), 0.6% (v/v) 1-butanol and 0.5%  
65 (v/v) ethyl acetate. The result showed that the migration time  
66 and resolution increased with the increase of pH value.  
67 Considering the poor separation of N<sup>6</sup>-methyladenosine and  
68 cytidine, mercaptopurine and fluorouracil partly as pH below  
69 9.0, pH 9.0 was consequently selected in following  
70 experiments.

#### 14 Preparation of standard solutions and samples

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

71 The effect of concentration (5-15 mM) was also investigated.  
72 Unsurprisingly, higher concentration led to longer migration  
73 time and higher Joule heating while better separation was  
74 obtained. The concentration of 10 mM was selected as a  
75 compromise.

76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93

76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93

77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93

77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

#### 35 MEEKC and FASI procedures

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106



11.2 % (v/v), the result shown in Fig.2 indicated that no apparent change of separation occurred. Accounting of the stability of the microemulsion and separation of analytes, the final concentration of 1-butanol was set at 0.6 % (v/v).




Fig. 2 Effect of the concentration of cosurfactant. Conditions: 98.9 % (v/v) 10 mM borate buffer (pH 9.0) containing 10 mM SDS, 0.5 % (v/v) ethyl acetate; capillary, 63 cm (54.5 cm effective length)  $\times$  50  $\mu$ m *i.d.*  $\times$  375  $\mu$ m *o.d.* 25°C; applied voltage, 15 kV; electrokinetic injection, +10 kV for 6 s; detection wavelength, 200 nm; temperature, 25°C. Peaks: 1, cytidine (75.0  $\mu$ g/mL); 2, guanosine (50.0  $\mu$ g/mL); 3, N6-methyladenosine (100  $\mu$ g/mL); 4, fluorouracil (100  $\mu$ g/mL); 5, thymine (75.0  $\mu$ g/mL); 6, adenine (350  $\mu$ g/mL); 7, mercaptopurine (350  $\mu$ g/mL); 8, 6-hydroxypurine (125  $\mu$ g/mL); 9, guanine (75.0  $\mu$ g/mL).

The optimized separation condition was eventually summarized as follows: microemulsion consist of 98.9 % (v/v) 10 mM borate buffer (pH 9.0) with 10 mM SDS, 0.6 % (v/v) 1-butanol, and 0.5 % (v/v) ethyl acetate; applied voltage, +15 kV; electrokinetic injection, 10 kV for 6 s; detection wavelength, 200 nm. Under the optimized conditions, cytidine (75.0  $\mu$ g/mL); guanosine (50.0  $\mu$ g/mL); N6-methyladenosine (100  $\mu$ g/mL); fluorouracil (100  $\mu$ g/mL); thymine (75.0  $\mu$ g/mL); adenine (350  $\mu$ g/mL); mercaptopurine (50.0  $\mu$ g/mL); mercaptopurine (125  $\mu$ g/mL); and guanine (75.0  $\mu$ g/mL) were well separated and detected within 12 min (Fig.3).




Fig. 3 Electropherogram of nine nucleoside compounds in optimized MEEKC conditions. Conditions: 98.9 % (v/v) 10 mM borate buffer (pH 9.0) containing 10 mM SDS, 0.6 % (v/v) 1-butanol, and 0.5 % (v/v) ethyl acetate; applied voltage, 15 kV; electrokinetic injection, +10 kV for 6 s; detection wavelength, 200 nm. Peaks: 1, cytidine (75.0  $\mu$ g/mL); 2, guanosine (50.0  $\mu$ g/mL); 3, N6-methyladenosine (100  $\mu$ g/mL); 4, fluorouracil (100  $\mu$ g/mL); 5, thymine (75.0  $\mu$ g/mL); 6, adenine (350  $\mu$ g/mL); 7, mercaptopurine (350  $\mu$ g/mL); 8, 6-hydroxypurine (125  $\mu$ g/mL); 9, guanine (75.0  $\mu$ g/mL).

### Effect of oil phase

Oil, as the core phase, usually a hydrocarbon or other hydrophobic substance is enclosed by the surfactant with the aids of the co-surfactant.<sup>24, 27, 33</sup> Octane, ethyl acetate and cyclohexane were commonly used as the oil phase. It was concluded that under normal MEEKC conditions that variation in oil type had no significant effect on separation.<sup>26</sup> Ethyl acetate leads to microemulsions with a lower surface tension, meaning less surfactant was needed to stabilize the microemulsion.<sup>30</sup> The optimization was carried out on Ethyl acetate. The trials indicated that ethyl acetate in the range of 0.25 - 0.75 % achieved the separation of nine nucleotides without the degradation of the resolution and sensitivity. The 0.5 % (v/v) ethyl acetate was considered for the stability of microemulsion with a low concentration of SDS.


### Effect of separation voltage

The magnitude and direction of EOF, the resolution and sensitivity rely on the separation voltage as well. Without doubt, the migration time of nine analytes was gradually shortened by increasing separation voltage. However, the experiments also showed that the sensitivity and resolution decreased when the separation voltage exceed +15 kV due to the Joule heating created by larger current in the running buffer. In order to obtain both good resolution and short analytical time, a separation voltage of +15 kV was applied in this study.

### Optimization of FASI

As previously stated, on-line sample pre-concentration can improve the sensitivity of MEEKC methods and make it more suitable for the biological application. In this study, FASI, stacking ionic analytes at the interface between two zones of different conductivity, was adopted to be on-line coupled with MEEKC. Before sample injection, a low conductivity solvent was introduced at the inlet of the capillary previously filled with a high ionic strength running electrolyte. Then, the sample is electrokinetically injected and analytes are concentrated at the boundary between the pre-injection. Herein, four kinds of diluents including 10 mM borate buffer (pH 9.0), 0.1 M NaOH, methanol and the microemulsion were compared (Fig.4). We found that diluents have significant effect on both the resolution and sensitivity except 10 mM borate buffer (pH 9.0), which improve the sensitivity of all analytes with no obvious change in retention time. Consequently, 10 mM borate

1 buffer (pH 9.0) was selected as the diluents of sample for  
2 farther research.



3  
4 **Fig. 4** Effect of sample diluent on the enrichment of nine nucleoside compounds:  
5 (a) 10 mM borate buffer; (b) the microemulsion; (c) 0.1 mM NaOH; (d) methanol.  
6 Other conditions were same as in Fig. 6. Peaks: 1, cytidine (40.0 µg/mL); 2,  
7 guanosine (25.0 µg/mL); 3, N6-methyladenosine (50.0 µg/mL); 4, fluorouracil  
8 (50.0 µg/mL); 5, thymine (40.0 µg/mL); 6, adenine (175 µg/mL); 7,  
9 mercaptopurine (25.0 µg/mL); 8, 6-hydroxypurine (65.0 µg/mL); 9, guanine (40.0  
10 µg/mL).

11  
12 The injection time was investigated in the range of 5-30 s.  
13 Although prolonged time increase the sample amount, the peak  
14 shape and resolution deteriorated while the injection exceeded  
15 10 s. The electrokinetic injection condition was also optimized

16 by varying the injection voltage ranging +14-24 kV for 10 s. As  
17 expected, the higher injection voltage provided larger amount

18 of sample injection enhancing the response. Whereas the  
19 voltage exceeding +22 kV broadened peak shape and decreased

20 the resolution. The reasons may be that: (1) A overloading  
21 injection voltage led to a overloading injection volume (exceed

22 10% of the total volume of the capillary) causing peak  
23 broadening, resolution and sensitivity decreasing; (2) A


24 overloading injection voltage led to an increasing Joule heating  
25 generated in sample plug, which finally affect the stability of

26 the current and baseline of CE separation; (3) A overloading  
27 injection voltage led to unpredictable bubbles in the system

28 bringing conductance differences between sample diluents and  
29 running buffer. Taking the amount of injection and the

30 resolution into consideration, +22 kV×10 s was selected as the  
31 best injection condition in FASI.

32 Compared with normal electrokinetic injection, nine nucleoside  
33 compounds were well separated and the obtained enrichment  
34 factor was in the range of 4–35 in optimized FASI-MEEKC  
35 conditions. The optimal Electrochromatogram of nine nucleosides  
36 was shown in Fig. 5.



37  
38 **Fig. 5** Comparison of electrochromatograms between normal electrokinetic injection  
39 and FASI: (a) Normal electrokinetic injection: +10 kV for 6 s; Peaks: 1, cytidine (4.  
40 00 µg/mL); 2, guanosine (4.00 µg/mL); 3, N6-methyladenosine (5.00 µg/mL); 4,  
41 fluorouracil (10.0 µg/mL); 5, Thymine (8.00 µg/mL); 6, Adenine (60.0 µg/mL); 7,  
42 mercaptopurine (10.0 µg/mL); 8, 6-hydroxypurine (8.00 µg/mL); 9, Guanine (4.00  
43 µg/mL). (b) FASI: 22 kV for 10 s; Peaks: 1, cytidine (2.00 µg/mL); 2, guanosine  
44 (2.00 µg/mL); 3, N6-methyladenosine (2.50 µg/mL); 4, fluorouracil (5.00 µg/mL);  
45 5, thymine (4.00 µg/mL); 6, adenine (30.0 µg/mL); 7, mercaptopurine (5.0  
46 µg/mL); 8, 6-hydroxypurine (4.00 µg/mL); 9, guanine (2.00 µg/mL). Other  
47 conditions were the same as Fig. 3.

#### 49 Method Validation

50 Once the method had been established, completely study of  
51 linearity, detection limit and reproducibility of this FASI-  
52 MEEKC method was conducted by analysis of a series of  
53 standard mixtures and the data were summarized in Table 1.

54 The calibration curves of these nine analytes exhibited good  
55 linearity with  $R^2$  in the range of 0.9915–0.9951. The detection  
56 limits at  $S/N = 3$  were between 0.22 and 2.97 µg/mL.

57 To examine the precision of the proposed method, five  
58 continuous injections of a standard mixture solution with the  
59 concentration of 2.0 µg/mL for cytidine, 2.0 µg/mL for  
60 guanosine, 2.5 µg/mL for N6-methyladenosine, 5.0 µg/mL for

1 fluorouracil, 4.0 µg/mL for thymine, 30.0 µg/mL for adenine, 7  
 2 25.0 µg/mL for mercaptopurine, 4.0 µg/mL for 6-hydroxypurine  
 3 and 2.0 µg/mL for guanine were analyzed. The RSDs of peak  
 4 highs are in the range of 2.09–5.74% and the RSDs of the  
 5 retention time vary from 0.45 to 1.12%.

6  
 7 Table 1. Regression equation, linearity, detection limits and repeatability of the proposed method for the analysis of nine nucleoside compounds


Compound	Regression equation	R <sup>2</sup>	Linear range (µg/mL)	Detection limit (µg/mL)	RSD (n=5) (%)	
					Retention time (s)	Peak high (mAU)
cytidine	y=1.5118x+141.6	0.9936	1.22~75.0	0.41	0.89	3.18
guanosine	y=1.9214x+77.817	0.9937	0.65~50.0	0.22	0.68	5.74
N6-methyladenosine	y=0.9553x+80.454	0.9931	2.04~100	0.68	0.91	3.04
fluorouracil	y=1.2574x+54.756	0.9944	2.04~100	0.68	0.88	5.05
thymine	y=0.4199x+69.867	0.9920	1.22~75.0	0.41	1.05	2.09
adenine	y=0.1317x+73.636	0.9951	8.92~350	2.97	1.12	3.43
mercaptopurine	y=0.6143x+67.26	0.9935	0.65~50.0	0.22	0.65	2.98
6-hydroxypurine	y=1.4992x+19.185	0.9920	2.55~125	0.85	0.45	4.32
guanine	y=1.7018x+16.281	0.9915	1.22~75.0	0.41	0.54	4.46

9 The conditions were the same as in Fig. 3. y: peak high, (mAU); x: mass concentration, µg/mL

### 10 11 Sample analysis and recovery


31 sample, and in the range of 85.2-112% with the RSDs of  
 32 peak areas less than 8.22 % in serum.

12  
 13 To evaluate the verification of the proposed method, urine  
 14 and serum samples were analyzed. The blank urine and  
 15 serum sample were respectively spiked with the standard  
 16 mixture at certain concentration (cytidine, 2.0 µg/mL;  
 17 guanosine, 2.0 µg/mL; N6-methyladenosine, 2.50 µg/mL;  
 18 fluorouracil, 5.0 µg/mL; thymine, 4.0 µg/mL; adenine, 30.0  
 19 µg/mL; mercaptopurine, 5.0 µg/mL; 6-hydroxypurine, 4.0  
 20 µg/mL; guanine, 2.0 µg/mL) and pretreated as described  
 21 previously. Fig.6 and Fig.7 respectively showed the  
 22 electropherograms of the urine samples and serum samples,  
 23 illustrating the analytes in the spiked samples were well  
 24 separated and detected without interference of impurity  
 25 peaks. Recoveries of the proposed method were further  
 26 investigated by spiking different concentrations of the  
 27 standard mixture into urine and serum samples. From the  
 28 data displayed in Table 2 and 3, we can found that the  
 29 recoveries of these analytes were in the range of 91.2-113%  
 30 with the RSDs of peak highs less than 5.90% in urine



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 Fig.6 Electropherogram of nine nucleoside compounds in spiked urine  
3 sample (a) and blank urine sample (b). Conditions were the same as Fig. 3.



4  
5  
6  
7  
8  
9  
10  
11  
12  
13

4  
5 Fig.7 Electropherogram of nine nucleoside compounds in spiked serum  
6 sample (a) and blank serum sample (b). Conditions were the same as Fig. 3.



**1 Table 2.** Recovery of nine nucleoside compounds in urine sample

Compound	Added (µg/mL)	Found (µg/mL)	Recovery (%)	RSD (n=3) (%)
cytidine	50.0	45.6	91.2	2.16
	5.00	5.45	109	3.89
guanosine	30.0	29.7	99.0	4.13
	5.00	4.89	97.8	5.67
N6-methyladenosine	50.0	48.6	97.2	2.98
	10.0	9.87	98.7	4.12
fluorouracil	50.0	52.9	106	2.79
	10.0	11.3	113	3.12
thymine	50.0	48.9	97.8	2.36
	5.00	5.01	100	4.78
adenine	100	99.7	99.7	2.21
	20.0	21.5	108	3.78
mercaptopurine	30.0	32.8	109	4.13
	5.00	4.90	98.0	5.90
6-hydroxypurine	50.0	50.6	101	4.41
	10.0	9.89	98.9	5.78
guanine	50.0	51.2	102	2.25
	5.00	4.78	96.0	4.01

2 The conditions were the same as in Fig. 3.

3

6

## 7 Conclusions

8 A stable, isotropically MEEKC method was on-line  
 9 combined with FASI for the determination of nucleoside  
 10 compounds. Herein, the MEEKC offered the rapid  
 11 separation, and the FASI significantly improved the  
 12 detection sensitivity of the analytes. The highly efficient and  
 13 sensitive hyphenation has been successfully applied to the  
 14 determination of human urine and serum. We expect that its  
 15 significance for routine analysis will continue in further  
 16 studies, so that it can be easily used for the monitoring the  
 17 nucleoside compounds in disease diagnosis, or possibly  
 18 promotes the application prospect in the nucleoside profile  
 19 information natural pharmaceutical chemistry,  
 20 pharmaceutical analysis.

21  
 22

**4 Table 3.** Recovery of nine nucleoside compounds in serum sample

Compound	Added (µg/mL)	Found (µg/mL)	Recovery (%)	RSD (n=3) (%)
cytidine	50.0	42.6	85.2	4.75
	5.00	5.05	101	5.39
guanosine	30.0	31.7	106	5.43
	5.00	4.57	91.4	6.66
N6-methyladenosine	50.0	49.1	98.2	5.18
	10.0	9.77	97.7	8.22
fluorouracil	50.0	55.9	112	3.99
	10.0	9.3	93.0	4.02
thymine	50.0	48.9	97.8	6.36
	5.00	5.32	105	7.58
adenine	100	96.4	96.4	5.05
	20.0	18.9	94.5	7.18
mercaptopurine	30.0	29.8	99.3	5.19
	5.00	4.44	88.0	6.67
6-hydroxypurine	50.0	47.6	95.2	6.43
	10.0	9.14	91.4	7.78
guanine	50.0	54.9	110	5.29
	5.00	5.38	108	6.31

5 The conditions were the same as in Fig. 3.

## 23 Acknowledgements

24 This project was financially supported by NSFC (21075016  
 25 and 21275029), National Basic Research Program of China  
 26 (No.2010CB732403), the Cultivation Fund of the Key  
 27 Scientific and Technical Innovation Project, Ministry of  
 28 Education of China (708056), the Program of the Industrial  
 29 Technology Development of Fujian Province, the Key  
 30 Special Purpose Funding of Physical Education Bureau of  
 31 Fujian Province (HX2005-74), the Program for Changjiang  
 32 Scholars and Innovative Research Team in University (No.  
 33 IRT11116). The authors also specially thank to Agilent  
 34 Technologies Co., Ltd.  
 35

## 36 Notes and references

37<sup>a</sup> Ministry of Education Key Laboratory of Analysis and Detection for  
 38 Food Safety, Fujian Provincial Key Laboratory of Analysis and

1 Detection for Food Safety, college of chemistry, Fuzhou University,  
 2 Fuzhou, Fujian, 350002, China  
 3<sup>b</sup> Analytical and Testing Center, The Sport Science Research Center,  
 4 Fuzhou University, Fuzhou, Fujian, 350002, China

5  
 6 † Corresponding author: Lan Zhang (zlan@fzu.edu.cn)

10 REFERENCE

- 11 1. B. Feng, M. H. Zheng, Y. F. Zheng, A. G. Lu, J. W.  
 12 Li, M. L. Wang, J. J. Ma, G. W. Xu, B. Y. Liu and  
 13 Z. G. Zhu, *Journal of gastroenterology and*  
 14 *hepatology*, 2005, 20, 1913-1919.  
 15 2. Y. Ma, G. Liu, M. Du and I. Stayton,  
 16 *Electrophoresis*, 2004, 25, 1473-1484.  
 17 3. H. Y. Cheung, C. W. Ng and D. J. Hood, *J.*  
 18 *Chromatogr. A*, 2001, 911.  
 19 4. L. Simeone, G. Mangiapia, G. Vitiello, C. Irace,  
 20 A. Colonna, O. Ortona, D. Montesarchio and L.  
 21 Paduano, *Bioconjugate chemistry*, 2012, 23,  
 22 758-770.  
 23 5. T. Nhujak, M. Srisa-art, K. Kalampakorn, V.  
 24 Tolieng and A. Petsom, *J. Agric. Food Chem.* ,  
 25 2005, 53, 1884-1889.  
 26 6. T. H. Senanayake, G. Warren and S. V.  
 27 Vinogradov, *Bioconjugate chemistry*, 2011, 22,  
 28 1983-1993.  
 29 7. S. Wang, X. Zhao, Y. Mao and Y. Cheng, *J.*  
 30 *Chromatogr. A*, 2007, 1147, 254-260.  
 31 8. G. Nass, *Modified Nucleosides and Cancer*,  
 32 Springer-Verlag, New York, 1983.  
 33 9. G. Schoech, G. Sander, H. Topp, G. Heller-  
 34 Schoch, C. W. Gehrke and K. C. Kuo,  
 35 *Chromatography and Modification of*  
 36 *Nucleosides, Part C*, Elsevier, Amsterdam, 1990.  
 37 10. H. M. Liebich, G. Xu, C. Di Stefano and R.  
 38 Lehmann, *J. Chromatogr. A* 1998, 793  
 39 11. C. B. Jendresen, M. Kilstrup and J.  
 40 Martinussen, *Anal. Biochem.*, 2011, 409, 249-  
 41 259.  
 42 12. T. Cserháti and E. Forga'cs, *J. Biochem.*  
 43 *Biophys. Methods*, 1999, 41, 21-30.  
 44 13. A. J. R. Teixeira, J. H. Gommers-Ampt, G. V.  
 45 deWerken, J. G. Westra, J. F. C. Stavenuiter and  
 46 A. P. J. M. de Jong, *Anal. Biochem.*, , 1993, 214,  
 47 474-483.  
 48 14. J. Ravanat, P. Guicherd, Z. Tuce and J.  
 49 Cadet, *Chem. Res. Toxicol.* , 1999, 12, 802-808.  
 50 15. N. Mesplet, P. Morin, C. Francois and L. A.  
 51 Agrofoglio, *Anal. Chem.*, 2008, 80, 1263-1271.  
 52 16. P. Schmitt-Kopplin and M. Frommberger,  
 53 *Electrophoresis*, 2003, 24, 3837-3867.  
 54 17. Y. Q. Jiang and Y. F. Ma, *Anal. Chem.* ,  
 55 2009, 81, 6474-6480
- 56 18. N. Mesplet, P. Morin, C. Francois and L. A.  
 57 Agrofoglio, *J. Chromatogr. A*, 2001, 927  
 58 161-168.  
 59 19. N. Mesplet, P. Morin and L. A. Agrofoglio,  
 60 *Electrophoresis*, 2002, 23 1263-1271.  
 20. P. Schmitt-Kopplin, *Capillary*  
 21 *Electrophoresis Method and Protocols*,  
 22 Humana Press, Totowa, 2008  
 23 21. S. Viglio, M. Fumagalli, F. Ferrari, A.  
 24 Bardoni, R. Salvini, S. Giuliano and P.  
 25 Iadarola, *Electrophoresis*, 2012, 33, 36-47.  
 26 22. Z. Chen, Z. Lin, L. Zhang, Y. Cai and L.  
 27 Zhang, *The Analyst*, 2012, 137, 1723-1729.  
 28 23. B. Fogarty, E. Dempsey and F. Regan, *J.*  
 29 *Chromatogr. A*, 2003, 1014, 129-139.  
 30 24. L. S. Yu, K. D. Chu, H. Z. Ye, X. X. Liu, L. S.  
 31 Yu, X. Q. Xu and G. N. Chen, *TrAC*, 2012,  
 32 34, 140-151.  
 33 25. M. Geiger, A. L. Hogerton and M. T.  
 34 Bowser, *Anal. Chem.*, 2012, 84, 577-596.  
 35 26. R. Ryan, S. Donegan, J. Power, E. McEvoy  
 36 and K. Altria, *Electrophoresis*, 2009, 30, 65-  
 37 82.  
 38 27. M. D. Mertzman and J. P. Foley, *J.*  
 39 *Chromatogr. A*, 2005, 1073, 181-189.  
 40 28. P. Puig, F. Borrull, M. Calull and C. Aguilar,  
 41 *Chromatographia*, 2005, 62, 603-610.  
 42 29. J. Zhu, S. Qi, H. Zhang, X. Chen and Z. Hu, *J.*  
 43 *Chromatogr. A*, 2008, 1192, 319-322.  
 44 30. P. Puig, F. Borrull, C. Aguilar and M. Calull,  
 45 *Journal of chromatography. B, Analytical*  
 46 *technologies in the biomedical and life*  
 47 *sciences*, 2006, 831, 196-204.  
 48 31. H. F. Fang, Z. R. Zeng, L. Liu and P. D. W.,  
 49 *Anal. Chem.* , 2006, 78 1257-1263.  
 50 32. E. Liotta, R. Gottardo, C. Seri, C. Rimondo,  
 51 I. Miksik, G. Serpelloni and F. Tagliaro,  
 52 *Forensic science international*, 2012, 220,  
 53 279-283.  
 54 33. X. Y. Fu, J. D. Lu and Z. A., *J. Chromatogr.*  
 55 *A*, , 1996, 735 353-356.